166 related articles for article (PubMed ID: 35788405)
1. Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.
Kalchiem-Dekel O; Falcon CJ; Bestvina CM; Liu D; Kaplanis LA; Wilhelm C; Eichholz J; Harada G; Wirth LJ; Digumarthy SR; Lee RP; Kadosh D; Mendelsohn RB; Donington J; Gainor JF; Drilon A; Lin JJ
J Thorac Oncol; 2022 Sep; 17(9):1130-1136. PubMed ID: 35788405
[TBL] [Abstract][Full Text] [Related]
2. Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series.
Fricke J; Wang J; Gallego N; Mambetsariev I; Kim P; Babikian R; Chen BT; Afkhami M; Subbiah V; Salgia R
Clin Lung Cancer; 2023 Nov; 24(7):666-671. PubMed ID: 37580188
[No Abstract] [Full Text] [Related]
3. Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib.
Prete A; Gambale C; Cappagli V; Bottici V; Rossi P; Caciagli M; Papini P; Taddei D; Ortori S; Gabbrielli L; Celi A; Materazzi G; Elisei R; Matrone A
Eur J Endocrinol; 2022 Dec; 187(6):905-915. PubMed ID: 36314655
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
[TBL] [Abstract][Full Text] [Related]
5. Chylothorax and chylous ascites due to malignant lymphoma.
Oosterbosch L; Leloup A; Verstraeten P; Jordens P
Acta Clin Belg; 1995; 50(1):20-4. PubMed ID: 7725834
[TBL] [Abstract][Full Text] [Related]
6. Interventional treatment of refractory non-traumatic chylous effusions in patients with lymphoproliferative disorders.
Wagenpfeil J; Hoß K; Henkel A; Kütting D; Luetkens JA; Feldmann G; Brossart P; Attenberger UI; Pieper CC
Clin Exp Med; 2024 Mar; 24(1):63. PubMed ID: 38554229
[TBL] [Abstract][Full Text] [Related]
7. Progress and challenges in RET-targeted cancer therapy.
Hu X; Khatri U; Shen T; Wu J
Front Med; 2023 Apr; 17(2):207-219. PubMed ID: 37131086
[TBL] [Abstract][Full Text] [Related]
8. Recalcitrant chylothorax and chylous ascites associated with hypothyroidism.
Kollef MH
Mil Med; 1993 Jan; 158(1):63-5. PubMed ID: 8437744
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of systemic lupus erythematosus with chylothorax and/or chylous ascites: An analysis of 15 cases in China.
Zhang GH; Zhang LL; Wang YH; Shen WB
Medicine (Baltimore); 2020 Dec; 99(51):e23661. PubMed ID: 33371102
[TBL] [Abstract][Full Text] [Related]
10. Congenital fetal and neonatal visceral chylous effusions: neonatal chylothorax and chylous ascites revisited. A multicenter retrospective study.
Bellini C; Ergaz Z; Radicioni M; Forner-Cordero I; Witte M; Perotti G; Figar T; Tubaldi L; Camerini P; Bar-Oz B; Yatsiv I; Arad I; Traverso F; Bellini T; Boccardo F; Campisi C; Dalmonte P; Vercellino N; Manikanti S; Bonioli E
Lymphology; 2012 Sep; 45(3):91-102. PubMed ID: 23342929
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Sun F; McCoach CE
Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
[TBL] [Abstract][Full Text] [Related]
12. Chylous Ascites Developing Into Bilateral Chylothorax in High-Grade Lymphoma: A Case Report.
Avon JT; Gerrard AJ; Patel BB
Cureus; 2023 Apr; 15(4):e37344. PubMed ID: 37182072
[TBL] [Abstract][Full Text] [Related]
13. Pleural fluid analysis in chylous pleural effusion.
Agrawal V; Doelken P; Sahn SA
Chest; 2008 Jun; 133(6):1436-1441. PubMed ID: 18339791
[TBL] [Abstract][Full Text] [Related]
14. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
15. How we approach pediatric congenital chylous effusions and ascites.
Nakano TA; Dori Y; Gumer L; Liptzin DR; Hill LRS; Kulungowski AM
Pediatr Blood Cancer; 2022 Aug; 69 Suppl 3():e29246. PubMed ID: 36070215
[TBL] [Abstract][Full Text] [Related]
16. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
17. Use of Propranolol in the Treatment of Chylous Effusions in Infants.
Mitchell K; Weiner A; Ramsay P; Sahni M
Pediatrics; 2021 Jul; 148(1):. PubMed ID: 34187907
[TBL] [Abstract][Full Text] [Related]
18. Chylous Ascites as a Possible Rare Side Effect of Selpercatinib in RET-Positive NSCLC.
De Carlo E; Bertoli E; Chimienti E; Del Conte A; Bearz A
J Thorac Oncol; 2023 Feb; 18(2):e11-e13. PubMed ID: 36682840
[No Abstract] [Full Text] [Related]
19. [Medical treatment of chylous effusions in newborn infants. Apropos of 3 cases].
Jernite M; Donato L; Favre R; Haddad J; Esposito M; Messer J
Arch Fr Pediatr; 1992 Nov; 49(9):811-4. PubMed ID: 1300971
[TBL] [Abstract][Full Text] [Related]
20. Chylothorax in cirrhosis of the liver: analysis of its frequency and clinical characteristics.
Romero S; Martín C; Hernandez L; Verdu J; Trigo C; Perez-Mateo M; Alemany L
Chest; 1998 Jul; 114(1):154-9. PubMed ID: 9674463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
